No increase in risk of death for patients with well-controlled HIV, reports AIDS journal

With undetectable virus and normal immune function, mortality risk no higher than in general population, reports AIDS journal

2013-03-11

(Press-News.org) Philadelphia, Pa. (March 11, 2013) – For HIV-infected patients whose disease is well-controlled by modern treatment, the risk of death is not significantly higher than in the general population, according to a study published in AIDS, official journal of the International AIDS Society. AIDS is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

The study suggests that patients with undetectable viral loads and near-normal levels of immune cells on state-of-the art antiretroviral therapy (ART) can expect to have about the same risk of death as people without HIV. The article is available on the AIDS journal homepage and in the March 13 print edition.

What's the Risk of Death with Well-Controlled HIV? Dr Alison Rodger of University College London and colleagues assessed mortality rates in a group of patients with "optimally treated" HIV, drawn from two major trials of treatment for HIV infection: the ESPRIT and SMART trials. The analysis included nearly 3,300 patients who were not injecting drug users and who received continuous ART. On treatment, all had achieved undetectable HIV levels and had relatively high levels of CD4+ cells, a key population of immune cells—at least 350 cells/mm3. (A CD4+ cell count of 500 to 1,000 cells/mm3 is considered normal.)

The patients' average age was 43 years; 80 percent were men. Rates and causes of death in these patients with well-controlled HIV were compared with those in the general population.

During a median follow-up of about three years, 62 of the patients died. The most common causes of death were cardiovascular disease or sudden death, responsible for 31 percent of deaths; and non-HIV-related cancers, 19 percent. Only two deaths (three percent) were considered AIDS-related.

Patients with below-normal CD4+ cell counts (350 to 499 cells/mm3) were at elevated risk of death. Based on the standardized mortality ratio, the risk of death in this group was 77 percent higher than in the general population.

With Normal CD4+ Cell Counts, No Increase in Mortality However, in HIV-infected patients with a CD4+ cell count of 500 cells/mm3 or higher, the risk of death was not significantly higher than in the general population. For this group, the risk of death was essentially normal regardless of how low the CD4+ cell count dipped during treatment, as long as it returned to normal.

Over the years, effective ART regimens for HIV infection have become simpler, less toxic, and more effective. "Due to the success of ART, it is relevant to ask if death rates in optimally treated HIV are higher than the general population," the researchers write.

Previous studies have suggested that, with successful treatment, mortality risk approaches that of people without HIV. However, these studies have had important limitations, including a lack of complete information on patient outcomes. The use of comprehensive follow-up data from the ESPRIT and SMART trials overcomes this limitation.

The new study provides the best evidence yet that, with effective ART that achieving good disease control, the mortality rate for people with HIV is essentially the same as in the general population. Dr Rodger and colleagues conclude, "Our data support the importance of early diagnosis and treatment to improve clinical outcomes and it is likely that much of the excess mortality associated with HIV would be preventable with timely diagnosis of HIV and initiation of ART."

Further studies will be needed to clarify the implications for HIV treatment, including the best time to start ART based on CD4+ cell counts. The researchers also note that other causes of illness or death emerge as the current generation of treated HIV-infected people continues to age.

"Rodger and colleagues add to the considerable body of evidence on which early treatment initiation guidelines are based," commented Veronica Miller, PhD, Director of the Forum for Collaborative HIV Research. "Together with studies indicating equal benefit across risk groups, including injecting drug users, as long as individuals are maintained in care, this study further validates universal testing with immediate linkage and retention in care policies."

### About AIDS AIDS publishes the very latest ground-breaking research on HIV and AIDS. Read by all the top clinicians and researchers, AIDS has the highest impact of all AIDS-related journals. With 18 issues per year, AIDS guarantees the authoritative presentation of even more significant advances. The Editors, themselves noted international experts who know the demands of HIV/AIDS research, are committed to making AIDS the most distinguished and innovative journal in the field. Visit the journal website at http://www.aidsonline.com.

About Lippincott Williams & Wilkins Lippincott Williams & Wilkins (LWW) is a leading international publisher of trusted content delivered in innovative ways to practitioners, professionals and students to learn new skills, stay current on their practice, and make important decisions to improve patient care and clinical outcomes. LWW is part of Wolters Kluwer Health, a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company with 2012 annual revenues of €3.6 billion ($4.6 billion).

ELSE PRESS RELEASES FROM THIS DATE:

Combination therapy provides similar clinical benefit as single drug treatment in MS

2013-03-11

People with multiple sclerosis (MS) who were treated with combination therapy did not see significant clinical benefit over those treated with single drug therapy, but combination therapy did reduce the development of new lesions, according to an international research team led by The Mount Sinai Medical Center. The findings, part of the largest-ever MS trial sponsored by the National Institutes of Health, are published in the March 11 issue of Annals of Neurology. In the Phase III CombiRx trial, researchers led by Fred Lublin, MD, of The Mount Sinai Medical Center, sought ...

Older adults benefit from home-based DVD exercise program

2013-03-11

CHAMPAIGN, Ill. — Fitness DVDs are a multimillion-dollar business, and those targeting adults over the age of 55 are a major part of the market. With names like "Boomers on the Move," "Stronger Seniors" and "Ageless Yoga," the programs promise much, but few have ever been rigorously tested. "There are tons of DVDs out there, 20 percent of them are purchased by older adults, and with few exceptions there is no evidence that they work," said University of Illinois kinesiology and community health professor Edward McAuley, who led a new study testing the efficacy of a home-based ...

Tiny piece of RNA keeps 'clock' running in earliest stages of life

2013-03-11

COLUMBUS, Ohio – New research shows that a tiny piece of RNA has an essential role in ensuring that embryonic tissue segments form properly. The study, conducted in chicken embryos, determined that this piece of RNA regulates cyclical gene activity that defines the timing of the formation of tissue segments that later become muscle and vertebrae. Genes involved in this activity are turned on and off in an oscillating pattern that matches the formation of each tissue segment. If the timing of these genes' activity doesn't remain tightly regulated, the tissue either won't ...

International conference to tackle climate-change threats to agriculture

2013-03-11

Scientists and policymakers from around the world will gather March 20-22 at the University of California, Davis, to grapple with the threats of climate change for global agriculture and recommend science-based actions to slow its effects while meeting the world's need for food, livelihood and sustainability. The Climate-Smart Agriculture Global Science Conference, planned in coordination with the World Bank, builds on a 2011 international meeting on this theme in the Netherlands. "Climate change, which brings severe weather events and more subtle but equally menacing ...

Fluoride in drinking water cuts tooth decay in adults

2013-03-11

A new study conducted by researchers at the University of North Carolina at Chapel Hill and the University of Adelaide, Australia, has produced the strongest evidence yet that fluoride in drinking water provides dental health benefits to adults, even those who had not received fluoridated drinking water as children. In the first population-level study of its kind, the study shows that fluoridated drinking water prevents tooth decay for all adults regardless of age, and whether or not they consumed fluoridated water during childhood. Led by UNC School of Dentistry faculty ...

Nonprofits a major source of employment growth globally

2013-03-11

A new report from the Johns Hopkins Institute for Policy Studies reveals that nonprofit organizations are major employers and major sources of employment growth in countries throughout the world. The report draws on new data generated by statistical offices in 16 countries that have implemented a new United Nations Handbook on Nonprofit Institutions. This Handbook calls on national statistical offices to report on the economic scale and composition of nonprofit organizations in their countries for the first time. Key findings to date from implementation of this Handbook, ...

A new drug reduces heart damage

2013-03-11

This press release is available in French. A single dose of an investigational anti-inflammatory drug called inclacumab considerably reduces damage to heart muscle during angioplasty (the opening of a blocked artery), according to a recent international clinical trial spearheaded by Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, affiliated with the University of Montreal. Presented today in San Francisco at the prestigious American cardiology conference, these findings show great promise. "Inclacumab could indeed become an ...

Significant reduction in temperature and vegetation seasonality over northern latitudes

2013-03-11

An international team of authors from 17 institutions in seven countries, including the Woods Hole Research Center, published a study in the journal Nature Climate Change on the 10 March 2013 (10.1038/NCLIMATE1836: http://www.nature.com/nclimate). The study shows that, as the cover of snow and ice in the northern latitudes has diminished in recent years, the temperature over the northern land mass has increased at different rates during the four seasons, causing a reduction in temperature and vegetation seasonality in this area. The temperature and vegetation at northern ...

Can hormone help treat multiple sclerosis long-term?

2013-03-11

SAN DIEGO – A new study suggests that treatment with adrenocorticotropic hormone (ACTH) may be helpful for people whose multiple sclerosis (MS) is not well-controlled through their regular treatment. The study was released today and will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013. The study involved 23 people with MS who were taking beta-interferon treatment and had at least one relapse or brain scan showing new disease activity within the previous year. They were considered to have "breakthrough" MS, which ...

Early detection of MS treatment complication may improve survival

2013-03-11

SAN DIEGO – The drug natalizumab is effective for treating multiple sclerosis (MS), but it increases the risk of a rare but potentially fatal brain infection called progressive multifocal leukoencephalopathy (PML). A study released today that will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013, suggests that early detection of PML may help improve survival and disability levels. The study examined 319 people with MS who were treated with natalizumab and diagnosed with PML. Because of the risk of PML, people ...